QPS Holdings (QPS), a global contract research organization (CRO) that provides drug discovery, preclinical research, bioanalysis, clinical trials, and clinical research services, has recently expanded and updated its mass spectrometer equipment. This includes the installation of the new TripleTOF® 6600 for GLP quantification in Groningen, Netherlands, reinforcing its efforts to offer qualitative and quantitative bioanalysis of biopharmaceuticals in Europe.

Daniel Schulz-Jander, MSc, Ph.D., Senior Director of Bioanalysis at QPS, is set to lead the quantification team responsible for the expanded liquid chromatography mass spectrometry analysis of biopharmaceuticals and biomarkers at the QPS laboratory in the Netherlands.

The Sciex quadrupole time-of-flight high-resolution mass spectrometer, specialized for GLP/GCP quantification in oligonucleotide therapeutics, will be used to expand the oligonucleotide metabolite identification facility in Groningen.

Dr. Zamas Ram, Global Head of Bioanalytical and Principal Development (Mass Spec) at QPS, has emphasized the company's commitment to meeting European clients' needs by expanding the ultra-performance liquid chromatography-high-resolution mass spectrometry (UPLC-HRMS) system in the Netherlands, focusing on oligonucleotide analysis. This expansion aligns with QPS's extensive history of supporting oligonucleotide drug development in the USA over the past 20 years.

Daniel Schulz-Jander highlighted the strategic importance of this expansion, stating that it comes at a critical time for QPS. He emphasized the company's global efforts and the increased priority of supporting new drug development, especially in the fields of nucleic acid therapeutics and protein drug development.

Daniel Schulz-Jander's background includes a bachelor's degree in chemistry, a Ph.D. in environmental chemistry, and industry experience in bioanalysis. From February 2022, he will serve as Senior Director of Bioanalysis Mass Spectrometry at QPS Netherlands, overseeing the analysis of small and large molecules using liquid chromatography mass spectrometry (LC-MS/MS) and inductively coupled plasma mass spectrometry (ICP/MS). He will lead a team supporting bioanalysis.

With this expansion, QPS's group is now equipped with all the LC-MS and other chromatography technologies required for PK/PD bioanalysis. They specialize in ultra-performance liquid chromatograph-high-resolution mass spectrometry (UPLC-HRMS), immunoaffinity ultra-performance liquid chromatograph-mass spectrometer (UPLC-MS/MS) (tandem mass spectrometry), or hybridization, for the quantification of oligonucleotides, peptides, intact proteins, and highly hydrophilic small molecule metabolite biomarkers using LC-fluorescence methods.

 

Source: businesswire.com

Report Abuse